Back to results
US 2026/0137819 A1Published application
Follicle-stimulating hormone receptor (fshr) targeted therapeutics and uses thereof
AssigneeRadionetics Oncology, Inc.
InventorsJian ZHAO, Mi CHEN, Yunfei ZHU, Yifeng XIONG, Junjie LIU
Life of this patent
Estimating the term…
Abstract
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
Claims134
A compound of Formula (A), or a pharmaceutically acceptable salt thereof,
- wherein:
- R is LA-LB-R6, -LA-(LB-R6)2, or -LA-(LB-R6) 3;
- LA is a linker or is absent;
- LB is a linker or is absent;
- R6 is a chelating moiety or a radionuclide complex thereof;
- Z is C1-C6 alkylene, C1-C6 alkylene-O—, —O—C1-C6 alkylene-, —C(═O)NR10—, —NR10C(═O)—, —NR10—, —O—, —S—, —S(═O)—, —SO2—, —NR10C, (═O)NR10—, or —CR10—NO—;
- each R10 is independently H or unsubstituted C1-C4 alkyl;
- Ligand is a small molecule modulator of the follicle-stimulating hormone receptor (FSHR);
- and
- y is 1, 2 or 3.
7 more elements
Dependencies are inferred from the claim text.